CareDx (NASDAQ:CDNA) Upgraded to Strong-Buy at Wall Street Zen

Key Points

• Wall Street Zen upgraded CareDx (CDNA) from a "buy" to a "strong-buy" in a research note issued Sunday, marking a notable bullish signal for the stock.
• CareDx reported Q results showing a beat—EPS $0.34 vs. $0.11 expected—and revenue of $117.7M, up 39.3% year‑over‑year, though the company still has a negative net margin and negative return on equity.
• Analysts remain mixed overall: MarketBeat data show an average rating of "Hold" with an average price target of $28.00, while the stock trades around $21.50 with a $1.11B market cap and a 52‑week range of $10.96–$23.24.

CareDx (NASDAQ:CDNA - Get Free Report) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research note issued on Sunday.

CDNA has been the topic of a number of other reports. BTIG Research raised their price objective on CareDx from $26.00 to $28.00 and gave the company a "buy" rating in a research note on Wednesday. Craig Hallum lowered shares of CareDx from a "buy" rating to a "hold" rating and set a $26.00 price objective for the company. in a report on Tuesday, January 6th. Weiss Ratings lowered shares of CareDx from a "hold (c-)" rating to a "sell (d)" rating in a report on Friday, February 27th. Finally, Wells Fargo & Company raised their price objective on shares of CareDx from $18.00 to $21.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 25th. Two analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, CareDx presently has an average rating of "Hold" and an average price target of $28.00.

CareDx Stock Performance

CDNA opened at $21.50 on Friday. The business's 50-day simple moving average is $18.52 and its 200 day simple moving average is $18.29. The firm has a market capitalization of $1.11 billion, a PE ratio of -134.38 and a beta of 2.49. CareDx has a 52-week low of $10.96 and a 52-week high of $23.24.

CareDx (NASDAQ:CDNA - Get Free Report) last announced its quarterly earnings results on Tuesday, April 28th. The company reported $0.34 EPS for the quarter, beating analysts' consensus estimates of $0.11 by $0.23. CareDx had a negative return on equity of 2.65% and a negative net margin of 2.01%.The company had revenue of $117.70 million during the quarter, compared to analysts' expectations of $102.03 million. During the same period in the prior year, the company earned $0.09 EPS. CareDx's revenue was up 39.3% compared to the same quarter last year. On average, research analysts forecast that CareDx will post 0.22 earnings per share for the current year.

Insider Transactions at CareDx

In other news, CEO John Walter Hanna, Jr. sold 10,282 shares of the business's stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $21.12, for a total transaction of $217,155.84. Following the transaction, the chief executive officer directly owned 676,475 shares in the company, valued at $14,287,152. The trade was a 1.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 4.40% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Quarry LP acquired a new position in shares of CareDx during the 4th quarter worth approximately $25,000. FNY Investment Advisers LLC acquired a new position in shares of CareDx during the 3rd quarter worth approximately $31,000. State of Alaska Department of Revenue acquired a new position in shares of CareDx during the 3rd quarter worth approximately $43,000. Meeder Asset Management Inc. acquired a new position in shares of CareDx during the 4th quarter worth approximately $79,000. Finally, Quantbot Technologies LP acquired a new position in shares of CareDx during the 3rd quarter worth approximately $89,000.

CareDx Company Profile

CareDx, Inc NASDAQ: CDNA is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company's core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.